Intersect ENT (XENT) Tops Q4 EPS by 13c

Intersect ENT (NASDAQ: XENT) reported Q4 EPS of ($0.16), $0.13 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $13.4 million versus the consensus estimate of $12.2 million.

For earnings history and earnings-related data on Intersect ENT (XENT) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• UBS Reiterates Buy Rating on Sysco (SYY) Following Trip to Company Headquarters